Aclaris Therapeutics, Inc. ACRS
5.15
(0.23)
(4.28%)
as of 25 Sep
- Market cap
- $589.0M
- P/E
- 0.0×
Follow ACRS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (59.10%) | (48.42%) | (50.20%) | (113.23%) |
+8 more TTM periods Free account |
|
| (41.07%) | (35.11%) | (34.10%) | (79.17%) | ||
ROIC |
(163.35%) | (131.57%) | (387.11%) | (396.16%) | |
Return on Tangible Assets |
(107.91%) | (83.32%) | (94.87%) | (186.98%) | |
Average Days of Receivables |
275.74 | 210.00 | 259.55 | 108.52 | |
Free Cash Flow per Share |
(0.44) | (0.41) | (0.39) | (0.35) | |
Free Cash Flow |
(62.18) | (52.29) | (47.22) | (43.01) | |
Capital Expenditures |
(0.12) | (0.08) | (0.11) | (0.09) | |
Piotroski F-Score |
3.00 | 2.00 | 2.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(28.71%) | (20.96%) | (24.31%) | (19.87%) | |
Accounts Receivable Turnover |
2.57 | 3.30 | 0.87 | 6.27 | |
Accounts Payable Turnover |
0.59 | 0.72 | 0.82 | 1.79 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
791.08 | 711.60 | 659.35 | 221.83 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
770.59% | 677.88% | 672.69% | 286.43% | |
Selling, General and Administrative Expense of Revenue |
282.74% | 269.82% | 280.76% | 135.63% | |
Share Based Compensation of Revenue |
141.82% | 143.98% | 158.24% | 78.25% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.82 | 0.75 | 0.73 | 0.30 | |
Depreciation/Fixed assets |
0.63 | 0.57 | 0.60 | 0.61 | |
Capex/Depreciation |
(0.28) | (0.19) | (0.24) | (0.18) | |
Revenue per Share |
0.06 | 0.07 | 0.06 | 0.13 | |
Operating CF per Share |
(0.43) | (0.41) | (0.38) | (0.35) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 | |
Net Profit Margin |
(921.50%) | (832.58%) | (829.58%) | (900.07%) |
Columns are period end dates